Hematologic Oncology

By Alan P. Skarbnik, MD, Novant Health Cancer Institute, Catherine C. Coombs, MD, UNC School of Medicine, Danielle M. Brander, MD, Duke Cancer Institute

Relapsed/Refractory CLL: Repeat Molecular Testing

By Alan P. Skarbnik, MD, Novant Health Cancer Institute, Catherine C. Coombs, MD, UNC School of Medicine, Danielle M. Brander, MD, Duke Cancer Institute

Therapeutic Sequencing in Relapsed/Refractory CLL

By Alan P. Skarbnik, MD, Novant Health Cancer Institute, Catherine C. Coombs, MD, UNC School of Medicine, Danielle M. Brander, MD, Duke Cancer Institute

CLL Patient Management During COVID-19 and Telehealth

By Alan P. Skarbnik, MD, Novant Health Cancer Institute, Catherine C. Coombs, MD, UNC School of Medicine, Danielle M. Brander, MD, Duke Cancer Institute

CLL Treatment Approaches During COVID-19

Latest Videos

Dr. Riedell on Unique Data Points from an Analysis in MCL

Dr. Sallman on the Responses to PRGN-3006 in Select AML and Higher-Risk MDS

Dr. Matthews on the Efficacy of CPX-351 Vs Venetoclax/Azacitidine in AML

Dr. Jain on the Utility of UCART22 in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Q&A: Early Treatment of CLL

Q&A: Modifying and Switching Therapies in CLL

Novel Treatments for the Management of CLL

Considerations for Selection and Use of Frontline Therapy in Mantle Cell Lymphoma

An Overview of Mantle Cell Lymphoma and Frontline Therapy

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

CME Content

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

In-Person + Virtual Event

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

In-Person + Virtual Event

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

March 24, 2026

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

More News

Frontline CLL: Treatment Algorithms

January 8th 2021

Minimal Residual Disease in CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

Frontline CLL Treatment With Fixed-Duration Regimens

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

Anti-BCL2/CD20 Combination Therapy for Frontline CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

Anti-CD20/BTKi Therapy for Frontline CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

BTK Monotherapy for Frontline CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

Selecting Frontline Therapy to Treat CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

Kendra Sweet, MD, of Moffitt Cancer Center

Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML

ByKendra Sweet, MD

January 7th 2021

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

Victor Moreno Garcia, PhD, director of Clinical Research at the Phase 1 Trials Unit START at University Hospital Fundación Jiménez Díaz

BET Inhibitor CC-90010 Shows Activity in Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma

ByHayley Virgil

January 7th 2021

January 7, 2021 - The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Kendra Sweet, MD, discusses efforts made to mitigate toxicities associated with ponatinib in patients with chronic lymphocytic leukemia.

Dr. Sweet on the Awareness and Mitigation of AEs Associated With Ponatinib in CML

ByKendra Sweet, MD

January 7th 2021

Kendra Sweet, MD, discusses efforts made to mitigate toxicities associated with ponatinib in patients with chronic myeloid leukemia.

Ruben Mesa, MD, executive director of The University of Texas San Antonio MD Anderson Cancer Center.

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

ByDenise Myshko

January 6th 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.

$relapsed/refractory large B-cell lymphoma$

Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review

January 4th 2021

January 4, 2021 - The biologics license application for the CAR T-cell product lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA, and a decision on the application has not yet been reached.

Iomab-B Conditioning Therapy Leads to 100% Transplant, Engraftment Rate in Active Relapsed/Refractory AML

ByGina Mauro

December 29th 2020

Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.

Joshua Brody, MD, of The Tisch Cancer Institute at Mount Sinai

Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies

ByJessica Hergert

December 28th 2020

Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.

Druker Details a Career of Determination, Patient Impact, and Family Success

ByOncLive Staff

December 24th 2020

In our exclusive interview, Brian Druker, MD, discusses his journey into the field of oncology, the research that led to the initial approval of imatinib, why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist.

Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma

ByKatie Kosko

December 23rd 2020

December 23, 2020 — Findings from the International, Prospective ALCL-Relapse trial showed that allogeneic SCT after reinduction chemotherapy can lead to survival improvements in children and adolescents with high-risk relapsed or refractory anaplastic large cell lymphoma, provide more insight into how to treat this population.

Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.

Dr. Lin on the Promise of Cilta-Cel and Ide-Cel in Myeloma

ByYi Lin, MD, PhD

December 21st 2020

Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.

Dr. Jain on the Role of BTK Inhibitors in MCL

ByPreetesh Jain, MD, PhD

December 21st 2020

Preetesh Jain, MD, PhD, discusses the role of BTK inhibitors in mantle cell lymphoma.

Gilteritinib/Azacitidine Fails to Significantly Improve OS in Newly Diagnosed FLT3+ AML

December 21st 2020

December 21, 2020 — The addition of gilteritinib to azacitidine failed to significantly improve overall survival vs azacitidine alone in patients with newly diagnosed FLT3-mutated acute myeloid leukemia who were not eligible for intensive induction chemotherapy, failing to meet the primary end point of the LACEWING trial.

Robert Iannone, MD, MSCE, Jazz Pharmaceuticals

BLA Initiated for JZP-458 in Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

December 21st 2020

December 21, 2020 - The submission of a biologics license application to the FDA has been initiated for JZP-458 for use as a component of a multiagent chemotherapy regimen in the treatment of adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.

FDA Approves Ponatinib for Resistant or Intolerant Chronic-Phase CML

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

December 18th 2020

December 18, 2020 - The FDA has approved ponatinib for the treatment of patients with chronic-phase chronic myeloid leukemia that is resistant or intolerant to at least 2 prior kinase inhibitors.

The Rationale for Targeting BCMA in Multiple Myeloma

December 18th 2020

Treatment Approach for R/R Multiple Myeloma

December 18th 2020

FDA Approves Rituximab Biosimilar for NHL, CLL, GPA, and MPA